Mobinitinib fumerate

N/A

Report date: 2025/05/23 14:39:03
NME

Base Information

Drug NameMobinitinib fumerate
Drug Alias NameEP-0042
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Aurora inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsSerine/threonine-protein kinase AuroraTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlandsAustraliaUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEllipses Pharma
China Registration ClassN/A

Develop Information

Active CompaniesEllipses Pharma
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A